BioAtla, Inc. (BCAB): Price and Financial Metrics

BioAtla, Inc. (BCAB): $1.59

0.04 (+2.58%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add BCAB to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#285 of 345

in industry

BCAB Price/Volume Stats

Current price $1.59 52-week high $9.87
Prev. close $1.55 52-week low $1.24
Day low $1.49 Volume 272,500
Day high $1.63 Avg. volume 502,176
50-day MA $1.60 Dividend yield N/A
200-day MA $2.61 Market Cap 76.22M

BCAB Stock Price Chart Interactive Chart >


BioAtla, Inc. (BCAB) Company Bio


BioAtla LLC develops conditionally active biologic antibody therapeutics. The firm's technologies include conditionally active biologics, comprehensive integrated antibody optimization, CPE and CPS, gigamab, and versitop. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.


BCAB Latest News Stream


Event/Time News Detail
Loading, please wait...

BCAB Latest Social Stream


Loading social stream, please wait...

View Full BCAB Social Stream

Latest BCAB News From Around the Web

Below are the latest news stories about BIOATLA INC that investors may wish to consider to help them evaluate BCAB as an investment opportunity.

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and scheduled one-on-one investor meetings at the JMP Securities Hematology and Oncology Summit, to be held virtually December 5–6, 2023. Format: Fireside chat and scheduled

Yahoo | November 30, 2023

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a virtual KOL Event on Monday, December 4, 2023 at 11:00 AM ET. To register, click here. The event will feature Carl M. Gay, MD, PhD (MD Anderson Cancer Center), who will review the Phase 2 clinical trial data of mecbotamab ved

Yahoo | November 28, 2023

BioAtla, Inc. (NASDAQ:BCAB) Q3 2023 Earnings Call Transcript

BioAtla, Inc. (NASDAQ:BCAB) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Good afternoon, ladies and gentlemen, and welcome to the BioAtla Third Quarter 2023 Earnings Call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] Please be advised that this call is […]

Yahoo | November 12, 2023

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

Observed additional clinical responses and FDA feedback supports path forward for CAB-AXL-ADC (BA3011) non-small cell lung cancer (NSCLC) registrational study; detailed interim Phase 2 data to be presented at upcoming IASLC conference in early December and discussed at KOL event on December 4, 2023Observed new PRs with CAB-ROR2-ADC (BA3021) Q2W dosing regimen in the Phase 2 melanoma study and a new PR with BA3021 2Q3W in the Phase 2 head and neck studyInitiated Phase 2 CAB-CTLA-4 (BA3071) study;

Yahoo | November 7, 2023

BioAtla to Participate in the Jefferies London Healthcare Conference

SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and scheduled one-on-one investor meetings at the Jefferies London Healthcare Conference, to be held in London, UK November 14–16, 2023. Format: Fireside chat and one-on-one

Yahoo | November 6, 2023

Read More 'BCAB' Stories Here

BCAB Price Returns

1-mo -3.64%
3-mo -33.47%
6-mo -56.44%
1-year -83.78%
3-year N/A
5-year N/A
YTD -80.73%
2022 -57.97%
2021 -42.28%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!